May 17, 2013 - ZOLL to Demonstrate New Pediatric CPR Electrodes, Advanced Resuscitation and Temperature Management Technologies at NTI 2013
MEDIA CONTACT: |
Diane Egan |
ZOLL TO DEMONSTRATE NEW PEDIATRIC CPR ELECTRODES, ADVANCED RESUSCITATION AND TEMPERATURE MANAGEMENT TECHNOLOGIES AT NTI 2013
May 17, 2013—CHELMSFORD, MASS.—ZOLL® Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it will display its fully integrated portfolio of resuscitation devices and temperature management technology that address each link in the Chain of Survival in Booth #2719 May 21-23 at the Association of Critical Care Nurses National Teaching Institute (NTI) & Critical Care Exposition in Boston.
ZOLL’s technology is strongly aligned with the emphasis on high-quality CPR and minimizing interruptions during chest compressions in the American Heart Association Guidelines.
New to the ZOLL portfolio are the OneStep™ Pediatric CPR Electrodes, which are the only electrodes on the market with a built-in CPR sensor that displays depth and rate of chest compressions during CPR on young children up to 8 years of age. This first-of-its-kind electrode provides optimal support for pediatric resuscitation when paired with the ZOLL R Series® Monitor/Defibrillator. The OneStep CPR Pediatric Electrodes can be used for monitoring, pacing, and defibrillation, as well as display CPR quality on the R Series CPR Dashboard™.
Another expanded capability of the R Series and CodeNet®, a hand-held electronic documentation system, is the transfer of a complete, synchronized code record by Wi-Fi. Now hospitals can rapidly and safely upload a complete code record for post-code data review and use the data for benchmarking and quality improvement. The R Series Code-Ready® family of defibrillators for hospitals also feature ZOLL’s proprietary Real CPR Help® audio and visual feedback for the correct depth, rate, and release velocity as well as tracking of idle time. The R Series also uses See-Thru CPR®, a breakthrough technology that filters out CPR artifact from the ECG to reduce CPR interruptions.
Also being showcased at NTI:
- The X Series® Monitor/Defibrillator is about half the size and half the weight of competitive full-featured monitor/defibrillators, yet much more powerful. This monitor/defibrillator combines the clinically superior therapeutic capabilities of ZOLL defibrillation, pacing, and CPR assistance with advanced monitoring parameters. The X Series has every advanced monitoring and communication capability required for critical care transport.
- The AutoPulse® Non-invasive Cardiac Support Pump is an automated, portable chest compression device. It is the only mechanical CPR system to have shown improved survival in comparative clinical trials. The AutoPulse more than tripled survival compared to typical CPR during witnessed shockable arrests1.
- The LifeVest® Wearable Defibrillator is worn by patients at risk for sudden cardiac arrest (SCA), providing protection during their changing condition and while permanent SCA risk has not been established. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm. The LifeVest is lightweight and easy to wear, and allows a patient’s physician time to assess his or her long-term arrhythmic risk and make appropriate plans.
- Intravascular Temperature Management (IVTM™) technology offers health care providers the power and control they need to rapidly, safely, and effectively manage the core body temperature of critically ill or surgical patients. The Thermogard XP® delivers accurate, easy-to-use and cost-effective control for both cooling and warming applications.
ZOLL Sponsors Three Education Sessions in Booth 2719
In keeping with the company’s vision to help improve resuscitation and increase survival rates, ZOLL will offer three 30-minute education sessions conducted by leading nursing instructors at scheduled times during exhibit hours. Session topics will include “Five Tips to Double (or Triple) Your Cardiac Arrest Survival,” “The ‘ART’ MATRIX: A Model for Inpatient Cardiac Arrest,” and “Therapeutic Hypothermia after Cardiac Arrest: Strategies for a Successful Program*.”
About ZOLL Medical Corporation
ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care. For more information, visit www.zoll.com.
About Asahi Kasei
The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 25,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.
©2013 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. AutoPulse, Code-Ready, CodeNet, CPR Dashboard, IVTM, LifeVest, R Series, Real CPR Help, See-Thru CPR, ThermoGuard XP, X Series, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All trademarks are the property of their respective owners. All product names are the property of their respective owners.
1Wik L, et al. The impact of CPR duration on survival to discharge between integrated AutoPulse-CPR and manual–CPR during out-of-hospital cardiac arrest of presumed cardiac origin. Resuscitation. 2012;83:e17
*This product is not cleared by the FDA for sudden cardiac arrest.